Form 8K Vaxart Inc For: 23 April
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Vaxart Inc (VXRT)
Vaxart Inc stock price live, this page displays OTC VXRT stock exchange data. View the VXRT premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Vaxart Inc real time stock price chart below.
What Is the Vaxart Inc Stock Price Today?
The Vaxart Inc stock price today is 0.7319.
What Is the Stock Symbol for Vaxart Inc?
The stock symbol for Vaxart Inc is "VXRT."
What Stock Exchange Does Vaxart Inc Trade On?
Vaxart Inc is listed and trades on the OTC Markets stock exchange.
Is Vaxart Inc a Good Stock to Buy?
Determining whether Vaxart Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the VXRT quote. (ISIN: US92243A2006)
What Is the Vaxart Inc Stock Price Today?
The Vaxart Inc stock price today is 0.7319.
What Is the Stock Symbol for Vaxart Inc?
The stock symbol for Vaxart Inc is "VXRT."
What Stock Exchange Does Vaxart Inc Trade On?
Vaxart Inc is listed and trades on the OTC Markets stock exchange.
Is Vaxart Inc a Good Stock to Buy?
Determining whether Vaxart Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the VXRT quote. (ISIN: US92243A2006)
0.7319
-0.0080(-1.08%)
Delayed Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.7100
0.7438
52 wk Range
0.2606
0.8449
Earnings results expected in 12 days
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.71000.7438
52 wk Range
0.26060.8449
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
VXRT Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
3.0000
Upside
+309.89%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Trading at a low revenue valuation multiple
- Vaxart adds James Breitmeyer to board of directors
- Investing.com
- Form 8K Vaxart Inc For: 23 April
- Investing.com
- Vaxart adds James Breitmeyer to board of directors
- Investing.com
- Form 8K Vaxart Inc For: 17 April
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Neutral
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; COVID-19 Vaccine, which is in Phase 2b clinical trial for the treatment of SARS-CoV-1, SARS-CoV-2, and Middle East respiratory syndrome coronavirus; Seasonal Influenza vaccine, which is in Phase 2 clinical trial, to treat H1N1 Influenza; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.
Vaxart Inc Earnings Call Summary for Q4/2025
- Vaxart reported Q4 2025 revenue of $237.3M, up 726% YoY, driven by BARDA contract and Dynavax partnership worth up to $700M total deal value.
- Stock declined 4.05% in regular trading despite strong results, but rebounded 4.15% pre-market; YTD gains reached 113% with analyst targets of $2-$4.
- Cash position of $63.8M extends runway into Q2 2027; company pursuing non-dilutive funding strategies to maintain financial flexibility.
- Dynavax collaboration includes $25M upfront payment with potential milestone payments and royalties; executives cite partnership as cornerstone of strategy.
- Key risks include dependence on government contracts, execution challenges on partnership milestones, and regulatory hurdles despite strong revenue growth.
Last Updated: 2026-03-12, 06:30 p/m
Read Full TranscriptCompare VXRT to Peers and Sector
Metrics to compare | VXRT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipVXRTPeersSector | |
|---|---|---|---|---|
P/E Ratio | 10.9x | −2.5x | −0.4x | |
PEG Ratio | 0.09 | −0.13 | 0.00 | |
Price/Book | 2.0x | 2.5x | 2.6x | |
Price / LTM Sales | 0.8x | 81.9x | 3.2x | |
Upside (Analyst Target) | 305.5% | 358.6% | 46.7% | |
Fair Value Upside | Unlock | 7.4% | 7.6% | Unlock |
Analyst Ratings
3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 3.0000
(+309.89% Upside)
Earnings
Latest Release
Mar 12, 2026
EPS / Forecast
-0.11 / -0.06
Revenue / Forecast
104.24M / 40.5M
People Also Watch
FAQ
What Is the Vaxart (VXRT) Stock Price Today?
The Vaxart stock price today is 0.7319 USD.
What Stock Exchange Does Vaxart Trade On?
Vaxart is listed and trades on the OTC Markets.
What Is the Stock Symbol for Vaxart?
The stock symbol for Vaxart is "VXRT."
What Is the Vaxart Market Cap?
As of today, Vaxart market cap is 176.6300M USD.
What Is Vaxart's Earnings Per Share (TTM)?
The Vaxart EPS (TTM) is 0.0700.
When Is the Next Vaxart Earnings Date?
Vaxart will release its next earnings report on May 06, 2026.
From a Technical Analysis Perspective, Is VXRT a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Vaxart Stock Split?
Vaxart has split 2 times.
How Many Employees Does Vaxart Have?
Vaxart has 65 employees.
What is the current trading status of Vaxart (VXRT)?
As of Apr 24, 2026, Vaxart (VXRT) is trading at a price of 0.7319 USD, with a previous close of 0.7399 USD. The stock has fluctuated within a day range of 0.7100 USD to 0.7438 USD, while its 52-week range spans from 0.2606 USD to 0.8449 USD.
What Is Vaxart (VXRT) Price Target According to Analysts?
The average 12-month price target for Vaxart is 3.0000 USD, with a high estimate of 4 USD and a low estimate of 2 USD. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +309.89% Upside potential.
What Is the VXRT Premarket Price?
VXRT's last pre-market stock price is 0.7787 USD. The pre-market share volume is 600.0000, and the stock has decreased by 0.0388, or 5.2400%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.